All existing shareholders including Alexandria Venture Investments contributed to the RNA drug developer’s series B round, following a $91.5m series A in mid-2020.

US-based RNA editing technology developer Korro Bio has secured $116m in a series B round featuring Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities.

The round was led by Eventide Asset Management and included investment and financial services group Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an unnamed healthcare specialist fund invested in the company, alongside all existing backers including Alexandria.

Founded in 2018, Korro is working…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn